trending Market Intelligence /marketintelligence/en/news-insights/trending/_xZelxn0_MgdtusD1AcPUg2 content esgSubNav
In This List

Apotex loses rights to launch authorized generic version of Egalet's nasal spray

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Apotex loses rights to launch authorized generic version of Egalet's nasal spray

Egalet Corp. said in a Form 8-K filing that Apotex Inc. and Apotex Corp. lost the right to launch an authorized generic version of its Sprix nasal spray.

Under a deal with Egalet, Apotex had rights to launch the generic version in March 2018. But the deal required Apotex to inform Egalet on or before Nov. 25 if it wished to exercise the launch option, which Apotex had not done, Egalet said.

If Apotex can meet requirements to launch an unauthorized generic, including getting an U.S. Food and Drug Administration approval of an abbreviated new drug application for its generic, it can launch in September 2018. Canada-based Apotex may also launch the generic six months earlier but it would then have to pay royalties on net sales of the drug from the launch date until December 2018, Egalet said in the filing.